Trade Alector, Inc. - ALEC CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.03
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.02226 %(-$2.23)Trade size with leverage ~ $10,000.00Money from leverage ~ $$9,000.00Go to platform: -0.02226%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position0.00004 %($0.00)Trade size with leverage ~ $10,000.00Money from leverage ~ $$9,000.00Go to platform: 0.00004%
• Overnight funding adjustment time: 22:00 (UTC)
• Currency: USD
• Min traded quantity: 10
• Margin: 10.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.02226 %
  (-$2.23)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: 0.00004 %
  ($0.00)

Key Stats

• Prev. Close: 2.43
• Open: 2.49
• 1-Year Change: 85.82%
• Day's Range: 2.29 - 2.56

Trade Alector, Inc. - ALEC

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer''s, Parkinson''s, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer''s and Parkinson''s diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer''s disease; and AL003, which is in Phase Ib clinical trial for the treatment of Alzheimer''s disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer''s disease; and 8 candidates in immuno-neurology/immuno-oncology field comprise ADP012, ADP016, ADP017, ADP023, ADP026, ADP122, ADP009, and ADP022. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.